Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.39−0.14 (-9.15%)
Close on Nov 18, 2026Market cap $270.38MP/E –Yield –
Altimmune net income
Net income is the profit left for shareholders after every expense, interest and tax.
Altimmune's net income for the twelve months ending Jun 30, 2026 was -$91.76M. For fiscal 2025 it was -$88.09M. The highest annual figure on record is -$3.44M in fiscal 2015.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$88.09M | – |
| FY2024 | Dec 31, 2024 | -$95.06M | – |
| FY2023 | Dec 31, 2023 | -$88.45M | – |
| FY2022 | Dec 31, 2022 | -$84.71M | – |
| FY2021 | Dec 31, 2021 | -$97.09M | – |
| FY2020 | Dec 31, 2020 | -$49.04M | – |
| FY2019 | Dec 31, 2019 | -$20.52M | – |
| FY2018 | Dec 31, 2018 | -$39.17M | – |
| FY2017 | Dec 31, 2017 | -$46.43M | – |
| FY2016 | Dec 31, 2016 | -$11.09M | – |
| FY2015 | Dec 31, 2015 | -$3.44M | – |
| FY2014 | Dec 31, 2014 | -$9.96M | – |
| FY2013 | Dec 31, 2013 | -$11.72M | – |
| FY2012 | Dec 31, 2012 | -$4.92M | – |
| FY2011 | Dec 31, 2011 | -$3.80M | – |
| FY2010 | Dec 31, 2010 | -$34.85M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.83M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.56M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$22.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$33.51M | – |
| Q2 FY2021 | Jun 30, 2021 | -$24.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.10M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.94M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.51M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.35M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.17M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.83M | -111.4% |
| Q3 FY2017 | Sep 30, 2017 | -$29.91M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.11M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.58M | – |
| Q4 FY2016 | Dec 31, 2016 | $77.80M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.80M | – |
See a number that looks wrong?